Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | CTSL | P07711 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325932 | 0.87 | CTRB1 (0.51) | CTRB1ATMSYKCTSKCTSL | |
| SCHEMBL4337923 | 0.86 | CTRB1 (0.52) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL4342809 | 0.83 | CTRB1 (0.53) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL2627396 | 0.80 | CTSK (0.62) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL29941638 | 0.80 | CTSK (0.62) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL10254381 | 0.80 | CTSK (0.62) | SYKCTSKCTSLCTSSCTSB | |
| SCHEMBL591895 | 0.80 | CTSK (0.59) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL2627373 | 0.80 | CTSK (0.59) | CTRB1ATMCTSKCTSLCTSS | |
| SCHEMBL8896054 | 0.80 | SYK (0.55) | CTRB1ATMSYKCTSKCTSL | |
| SCHEMBL591894 | 0.80 | CTSK (0.59) | CTRB1ATMCTSKCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2009-07-02 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| EP-1799222-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20060188920-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | BALZARINI JAN MARIA R | 2006-08-24 | — | — | US | disclosed |
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | BALZARINI JAN MARIA R | 2006-08-17 | — | — | US | disclosed |
| WO-2006030323-A2 | COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | TRIPEP AB (SE) | 2006-03-23 | — | — | WO | disclosed |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | TRIPEP AB (SE) | 2005-05-05 | — | — | US | disclosed |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | TRIPEP AB (SE) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183748-A1 | alpha-hydroxyglycinamide derivatives eg alpha -hydroxy-glycinamide hydrochloride | GALE, ENGASE, GLMN | CTRB1 2060/4885ATM 4561/4885SYK 3492/4885 |
| US-20050096319-A1 | Identification of compounds that inhibit replication of human immunodeficiency virus | GALE, ENGASE, GLMN | CTRB1 2676/4885ATM 4416/4885SYK 3583/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CTRB1 3205/4885ATM 4714/4885SYK 3178/4885 |
| US-20040180893-A1 | enzymatically or synthetically prepared alpha-hydroxyglycinamide inhibit the replication of HIV in human serum | ENGASE, GALE, OGA | CTRB1 1441/4885ATM 4023/4885SYK 3673/4885 |
| US-20090170953-A1 | INDENTIFICATION OF COMPOUNDS THAT INHIBIT REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS | OGA, ENGASE, GALE | CTRB1 3502/4885ATM 4052/4885SYK 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.